|Videos|August 30, 2021
Analyzing GEMINI 1 clinical trial results of presbyopia eye drop
Author(s)Sheryl Stevenson
Alex Delaney-Gesing
Alex Delaney-Gesing
George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
Advertisement
George O. Waring IV, MD, FACS, of the Waring Vision Institute (Mount Pleasant, SC), discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Related Articles
- Investigators share positive results of DAVIO 2 trial at EURETINA 2025
September 18th 2025
- Q&A: Peter Kiraly the value of the EBO course and exam at EURETINA 2025
September 17th 2025
- EyeCon 2025: Sun, sea, and a shared vision for the future of eye care
September 17th 2025
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Christine Kay, MD, on the 152-week results of the RESTORE study for retinitis pigmentosa
2
Virtual Vision Health and VirtuaLens enter partnership to accelerate virtual reality in eyecare
3
Part 6: What if? Curing any eye disease with the snap of your finger
4
Horus Pharma selected as additional commercialization partner for aflibercept biosimilar in Europe
5